Repligen logo

RGEN - Repligen Share Price

$208.89 -4.0  -1.9%

Last Trade - 4:06pm

Large Cap
Market Cap £8.48bn
Enterprise Value £8.14bn
Revenue £266.4m
Position in Universe 852nd / 6848
Unlock RGEN Revenue
Relative Strength (%)
1m +5.11%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.98%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
83.5 104.5 141.2 194 270.2 366.3 513.5 599.1 +34.4%
+24.6 +20.5 +9.6 -13.5 +85.7 +102.8 +22.2 +16.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, RepligenCorporation revenues increased 36% to $366.3M. Net incomeincreased from $21.4M to $59.9M. Revenues reflect Europesegment increase of 39% to $139.2M, North America segmentincrease of 28% to $175.8M. Net income benefited from Losson extinguishment of debt decrease from $5.7M (expense) to$0K, Other (expenses) income decrease of 32% to $214K(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RGEN
Graphical History


RGEN Revenue Unlock RGEN Revenue

Net Income

RGEN Net Income Unlock RGEN Revenue

Normalised EPS

RGEN Normalised EPS Unlock RGEN Revenue

PE Ratio Range

RGEN PE Ratio Range Unlock RGEN Revenue

Dividend Yield Range

RGEN Dividend Yield Range Unlock RGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RGEN EPS Forecasts Unlock RGEN Revenue
Profile Summary

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 29, 1981
Public Since April 29, 1986
No. of Shareholders: 307
No. of Employees: 1,128
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 54,771,343
Free Float (0.0%)
Eligible for
RGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RGEN
Upcoming Events for RGEN
Tuesday 4th May, 2021 Estimate
Q1 2021 Repligen Corp Earnings Release
Thursday 13th May, 2021 Estimate
Repligen Corp Annual Shareholders Meeting
Wednesday 28th July, 2021 Estimate
Q2 2021 Repligen Corp Earnings Release
Frequently Asked Questions for Repligen
What is the Repligen share price?

As of 4:06pm, shares in Repligen are trading at $208.89, giving the company a market capitalisation of £8.48bn. This share price information is delayed by 15 minutes.

How has the Repligen share price performed this year?

Shares in Repligen are currently trading at $208.89 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Repligen price has moved by 47.73% over the past year.

What are the analyst and broker recommendations for Repligen?

Of the analysts with advisory recommendations for Repligen, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Repligen is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Repligen next release its financial results?

Repligen is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Repligen dividend yield?

Repligen does not currently pay a dividend.

Does Repligen pay a dividend?

Repligen does not currently pay a dividend.

When does Repligen next pay dividends?

Repligen does not currently pay a dividend.

How do I buy Repligen shares?

To buy shares in Repligen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Repligen?

Shares in Repligen are currently trading at $208.89, giving the company a market capitalisation of £8.48bn.

Where are Repligen shares listed? Where are Repligen shares listed?

Here are the trading details for Repligen:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: RGEN
What kind of share is Repligen?

Based on an overall assessment of its quality, value and momentum, Repligen is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Repligen share price forecast 2021?

Shares in Repligen are currently priced at $208.89. At that level they are trading at 7.38% discount to the analyst consensus target price of 0.00.

Analysts covering Repligen currently have a consensus Earnings Per Share (EPS) forecast of 1.909 for the next financial year.

How can I tell whether the Repligen share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Repligen. Over the past six months, the relative strength of its shares against the market has been 5.67%. At the current price of $208.89, shares in Repligen are trading at 20.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Repligen PE Ratio?

The Repligen PE ratio based on its reported earnings over the past 12 months is 0.136k. The shares are currently trading at $208.89.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Repligen?

Repligen's management team is headed by:

Thomas Ryan - IND
Karen Dawes - CHM
Anthony Hunt - PRE
Nicolas Barthelemy - IND
Jon Snodgres - CFO
Glenn Muir - IND
Ralf Kuriyel - SVP
Rohin Mhatre - IND
Carrie Eglinton - DRC
Who are the major shareholders of Repligen?

Here are the top five shareholders of Repligen based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.05% (4.41m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.56% (4.14m shares)
Eddleman (Roy T) Individual Investor
Percentage owned: 6.39% (3.50m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 3.57% (1.95m shares)
Marshall Wace LLP Investment Advisor/Hedge Fund
Percentage owned: 3.17% (1.73m shares)
Similar to RGEN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.